Maze Therapeutics (NASDAQ:MAZE) Shares Down 5.9% - Here's What Happened

Key Points

• Maze Therapeutics' stock fell 5.9% to $14.02 after trading as low as $13.75, with a notable drop in trading volume by 76% from its average.
• Despite the recent decline, Wall Street analysts maintain a favorable outlook with an average rating of "Buy" and a consensus price target of $25.60.
• The company reported a loss of $1.15 per share in its latest quarterly earnings, missing the consensus estimate of ($0.76) by a significant margin.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price traded down 5.9% on Monday . The stock traded as low as $13.75 and last traded at $14.02. 49,062 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 202,594 shares. The stock had previously closed at $14.90.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wedbush assumed coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price target on the stock. HC Wainwright began coverage on shares of Maze Therapeutics in a report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of "Buy" and a consensus price target of $25.60.

Maze Therapeutics Price Performance

The business's 50-day simple moving average is $13.60.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently modified their holdings of the stock. CWM LLC purchased a new position in Maze Therapeutics in the 2nd quarter worth about $28,000. New York State Common Retirement Fund purchased a new position in Maze Therapeutics in the 1st quarter worth about $25,000. Corebridge Financial Inc. bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $57,000. Finally, Rhumbline Advisers bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $80,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.